An Experimental Drug for Alzheimer’s May Help Children with Autism

Written on |

Tel Aviv University Researchers Discover Alzheimer’s-Like Traits in Autistic Child’s Brain

An extensive international study led by Tel Aviv University, headed by Prof. Illana Gozes of the Department of Human Molecular Genetics and Biochemistry, found deposits of the tau protein typically found in Alzheimer’s patients in tissues taken from the postmortem brain of a 7-year-old autistic child. The child suffered from the ADNP syndrome, an ADNP mutation that causes a deficiency/malfunctioning of the ADNP protein which is essential for brain development. The ADNP syndrome child was characterized by severe developmental delay, intellectual disability, and autism. In light of these findings, the researchers tested an experimental drug called NAP – originally developed for Alzheimer’s disease – on nerve cells in a model of ADNP syndrome with the mutation inducing Alzheimer’s-like symptoms. The experiment was a success, with the damaged nerve – like cells returning to normal function.

The study was conducted in close collaboration with researchers from the Blavatnik School of Computer Science at Tel Aviv University, Sheba Medical Center, and a variety of research institutions across Europe, including the biotechnology institute BIOCEV in the Czech Republic, the Aristotle University of Thessaloniki in Greece, the University of Antwerp in Belgium, and the University Hospital Centre in Zagreb, Croatia. The article was published in July 2020 in the journal Translational Psychiatry printed by the Nature Publishing Group.

Prof. Gozes explains that the current study is based on tissues taken from the brain of a 7-year-old boy with ADNP syndrome who died in Croatia. “When we compared the postmortem ADNP syndrome brain tissues to tissue from the brain of a young person without ADNP syndrome, we found deposits of the tau protein in the ADNP child, a pathology that characterizes Alzheimer’s disease.”

The researchers then “treated” damaged nerve-like cells carrying an ADNP mutation, similar to the deceased child mutation with a drug candidate called NAP, which is developed in Prof. Gozes’s laboratory and originally intended to be used to help treat Alzheimer’s disease. “NAP is actually a short active fragment of the normal ADNP protein,” says Prof. Gozes. “When we added NAP to the nerve cells carrying an ADNP mutation, the tau protein bound to the nerve cell skeleton properly, and the cells returned to normal function.”

Prof. Gozes: “The fact that NAP treatment has been successful in restoring the normal function of neuronal-like cell models with impaired ADNP raises hopes that it may be used as a remedy for ADNP syndrome and its severe implications, including autism. Moreover, because other genetic disorders related to autism are characterized by tau pathologies in the brain, we hope that those suffering from these syndromes will also be able to benefit from NAP treatment in the future.” It is important to note that NAP (also called CP201) has been classified as an “orphan drug” by the US Food and Drug Administration, and is currently in the preparatory stages of a clinical trial in children with ADNP syndrome through the company Coronis Neurosciences.

In another phase of the study, the researchers sought to broaden their understanding of the effects of the mutation that causes ADNP syndrome. To do this, they extracted the genetic material mRNA (messenger RNA) from the tissues of the deceased child, and performed an expression analysis of about 40 proteins in the same child, encoded by the mRNA. Full genetic sequencing was also performed to determine protein expression in white blood cells taken from three other children with ADNP syndrome. An in-depth study was carried out on all of the data obtained in the genetic sequencing using advanced bioinformatics computational tools. The data were compared to online databases of protein expression data from healthy individuals, revealing a variety of characteristics that were common to the children with the syndrome, but very different from the normal appearance of these proteins.

Prof. Gozes concludes that “the significance of these findings is that the mutation that causes ADNP syndrome damages a wide range of essential proteins, some of which bind to, among other things, the tau protein, and impair its function as well. This creates various pathological effects in the brains (and other tissues) of children with ADNP syndrome, one of which is the formation of tau deposits, known to be a characteristic of Alzheimer’s disease. The vast and in-depth knowledge we have accumulated through the present study opens the door to further extensive and diverse research. We hope and believe that we will ultimately reach the goal of developing a drug or drugs that will help children with autism resulting from genetic mutations.”

Featured image: Prof. Illana Gozes

Related posts

Want to Live Longer? Find Out if You Snore

May 15, 2022

TAU Researchers Invent Healthy Weapon Against Covid

April 14, 2022

Is the Vaccine Safe? Consult the Smart Sensor!

April 11, 2022

TAU Nanodrug Enables 2-in-1 Attack on Cancer

April 5, 2022

Minor Head Injury Leads to Chronic Post-Concussion Syndrome in 1 of 4 Children

March 28, 2022

Inventive Study to Develop Biological Solutions for Agriculture

March 27, 2022

TAU Technology Could Prevent Repeat Heart Valve Surgery

March 24, 2022

Israeli Breakthrough in Treating PTSD

February 22, 2022

Can Higher Temperatures Accelerate the Rate of Evolution?

February 16, 2022

Discovery May Enable Early Diagnosis of Alzheimer’s

February 15, 2022

TAU Breakthrough Offers New Hope to Help People With Paralysis Walk Again

February 3, 2022

Ketogenic Diet Likely to Reduce Damage from Traumatic Brain Injuries

January 25, 2022

Reading Tea Leaves

January 25, 2022

Viruses and Game Theory

January 24, 2022

What’s The Link Between Electrical Voltage and Brain Adaptability?

January 23, 2022

As Pandemic Persists, TAU Forges Ahead with COVID-19 Research on All Fronts

December 30, 2021

Rising Temperatures Fuel Increase in Violence: TAU Study

December 26, 2021

Medicinal Cannabis Oil Effective for Treating Autism

December 22, 2021

Parent Smartphone Use Could Harm Child Development

December 19, 2021

Breakthrough TAU Discovery Key to Reversing ALS

December 16, 2021

Experimental Drug Displays Effectiveness in Treating Symptoms of Autism and Alzheimer’s Disease

December 15, 2021

Seaweed – A Promising Defense Against Covid-19

December 15, 2021

New Ethical Code for World Research of Ancient DNA

December 14, 2021

Saving Lives with Artificial Intelligence

December 9, 2021

TAU Experts on Omicron: “Don’t Panic”

December 7, 2021

Tired of The Lies?

November 23, 2021

Britain and Israel Team Up on Challenge of Healthy Ageing

November 10, 2021

TAU Researchers Identify COVID Proteins that Cause Strokes and Heart Attacks

November 8, 2021

Can’t Multitask Anymore?

October 6, 2021

Why Do We Squabble Over The AC?

October 5, 2021

The Immune System’s Double Agents

October 5, 2021

Help A Friend Out?

September 30, 2021

Using ‘Good’ Bacteria to Fight ‘Bad’ Bacteria

September 29, 2021

Recruiting ‘Fighting Cells’ to Destroy Tumors

September 14, 2021

TAU Team Reverses Early Signs of Alzheimer’s

September 10, 2021

Nicotine Testing of Children Curbs Parents’ Smoking

September 5, 2021

Want to Fall in Love? Step Outside in The Sun

August 31, 2021

The Silent Prophets

August 31, 2021

First 3D-bioprinting of entire active tumor

August 18, 2021

New Warning Sign for Breast Cancer

August 6, 2021

COVID-19 Immunity Varies Among Genders and Age Groups

July 26, 2021

Tel Aviv Bats Have More Fun

July 22, 2021

New study found differences between women and men in the level of COVID-19 antibodies

July 15, 2021

A world first: Technology that restores the sense of touch in nerves damaged as a result of amputation or injury

July 15, 2021

TAU Medical Student to Swim for Israel at Summer Olympics

July 15, 2021

New nanotech from TAU produces “healthy” electric current from the human body itself

July 9, 2021

Introducing the world’s thinnest technology – only two atoms thick

July 2, 2021

Want to Live a Long Life? Consider Investing in Your Marriage.

July 2, 2021

A world first: Targeted delivery of therapeutic RNAs only to cancer cells, with no harm caused to healthy cells

June 30, 2021

Combating Antibiotic Resistance

June 22, 2021

Pursuing the Unknown

Copyright ©  Tel Aviv University Trust. All rights reserved.
Registered charity number 314179.